Tarsus Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
TARS$73.83+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(In thousands, except share data)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2022 | 26,727,458 | $5 | $301,732 | $(74) | $(108,763) | $192,900 |
| Net loss | — | — | — | — | (135,893) | (135,893) |
| Recognition of stock-based compensation expense | — | — | 19,830 | — | — | 19,830 |
| Issuance of common stock, net of issuance costs of $6.9 million | 6,069,449 | — | 99,303 | — | — | 99,303 |
| Issuance of common stock under an at-the-market sale agreement, net of issuance costs of $0.8 million | 1,000,000 | — | 19,199 | — | — | 19,199 |
| Exercise of vested stock options | 136,310 | — | 592 | — | — | 592 |
| Issuance of common stock upon the vesting of restricted stock units | 206,813 | — | — | — | — | — |
| Shares issued in connection with the employee stock purchase plan | 71,160 | — | 985 | — | — | 985 |
| Other comprehensive income (loss) | — | — | — | 72 | — | 72 |
| Balance as of December 31, 2023 | 34,211,190 | $5 | $441,641 | $(2) | $(244,656) | $196,988 |
| Net loss | — | — | — | — | (115,554) | (115,554) |
| Recognition of stock-based compensation expense | — | — | 27,818 | — | — | 27,818 |
| Issuance of common stock, net of issuance costs of $6.7 million | 3,281,250 | 1 | 98,331 | — | — | 98,332 |
| Issuance of pre-funded warrants, net of issuance costs of $0.6 million | — | — | 9,365 | — | — | 9,365 |
| Exercise of vested stock options | 323,148 | — | 5,609 | — | — | 5,609 |
| Issuance of common stock upon the vesting of restricted stock units | 440,746 | — | — | — | — | — |
| Shares issued in connection with the employee stock purchase plan | 93,492 | — | 1,795 | — | — | 1,795 |
| Other comprehensive income (loss) | — | — | — | 181 | — | 181 |
| Balance as of December 31, 2024 | 38,349,826 | $6 | $584,559 | $179 | $(360,210) | $224,534 |
| Net loss | — | — | — | — | (66,418) | (66,418) |
| Recognition of stock-based compensation expense | — | — | 41,720 | — | — | 41,720 |
| Issuance of common stock, net of issuance costs of $9.0 million | 3,230,336 | — | 134,771 | — | — | 134,771 |
| Exercise of vested stock options | 307,192 | — | 6,280 | — | — | 6,280 |
| Issuance of common stock upon the vesting of restricted stock units | 598,256 | — | — | — | — | — |
| Shares issued in connection with the employee stock purchase plan | 68,321 | — | 2,337 | — | — | 2,337 |
| Other comprehensive income (loss) | — | — | — | 202 | — | 202 |
| Balance as of December 31, 2025 | 42,553,931 | $6 | $769,667 | $381 | $(426,628) | $343,426 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.